As recent researches revealed more and more key targets involved in NAFLD, a variety of new drugs (PPAR agonists, FXR agonists, ASK inhibitors, etc.)are being explored to treat NAFLD. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.